A 58-year-old postmenopausal woman from Delhi presents with abnormal uterine bleeding for 3 months. Pelvic examination reveals an enlarged uterus. Transvaginal ultrasound shows an endometrial thickness of 18 mm with irregular margins and heterogeneous echotexture. Endometrial biopsy reveals adenocarcinoma, grade 2, with invasion into the inner half of the myometrium. Staging CT chest and abdomen shows no distant metastases. What is the most appropriate next step in management?

Explanation

## Management of Early-Stage Endometrial Carcinoma ### Clinical Context This patient has: - Grade 2 adenocarcinoma (intermediate grade) - Stage IB disease (myometrial invasion ≤50%) - No distant metastases - Postmenopausal status with abnormal bleeding ### Surgical Management — The Gold Standard **Key Point:** Total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAH-BSO) is the cornerstone of treatment for all stages of endometrial cancer, regardless of grade or myometrial invasion depth [cite:Robbins 10e Ch 19]. **High-Yield:** For grade 2 tumors with myometrial invasion, pelvic and para-aortic lymph node dissection is indicated to: - Accurately stage the disease - Identify occult nodal metastases - Guide adjuvant therapy decisions - Improve overall survival ### Why Surgery is Mandatory | Feature | Significance | |---------|-------------| | Hysterectomy | Removes primary tumor and allows histological assessment | | BSO | Removes estrogen source; prevents ovarian metastases | | Lymphadenectomy | Staging; identifies 10–15% of patients with nodal disease | | Staging accuracy | Determines need for adjuvant radiotherapy or chemotherapy | ### Adjuvant Therapy Considerations After surgery, this patient (grade 2, stage IB) may require: - **Vaginal brachytherapy alone** if no adverse features - **External beam radiotherapy + chemotherapy** if high-intermediate risk (age >60, grade 2–3, LVSI, outer third invasion) **Clinical Pearl:** Surgical staging is essential before deciding on adjuvant therapy. Approximately 10–15% of clinically early-stage cancers have occult nodal involvement, which changes prognosis and treatment [cite:Park 26e Ch 11].